Skip to main content

Table 1 Characteristics of the three PDXs used

From: Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts

PDX ID

DIAGNOSIS

TP53 status

IHC

   

PTEN

NF1

p-ERK

MNHOC124

Serous/endometroid

mut

-

++

+++

MNHOC218

Endometroid

mut

-

+

++

MNHOC239

Serous

mut

-

++

++

  1. IHC Immunoistochemistry. Protein expression was cytoplasmic with no nuclear or membrane-associated staining. The intensity of the staining has been ranked according to the following scale: - negative; +/- slight/doubtful; + slight; ++ moderate; +++ marked
  2. Mut: mutated